Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses minimizing systemic DHT reduction using topical treatments for hair loss, specifically mentioning Minoxidil, Finasteride, and a proprietary carrier for DUT by XYON Health. The focus is on finding effective DHT blockers with minimal systemic absorption.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.

The conversation discusses using isotretinoin (Accutane) to reduce scalp oiliness and manage scalp issues like seborrheic dermatitis, inflammation, and chronic itch. A user shares that taking 20mg of Accutane every other day effectively reduces oily hair and skin.

The conversation humorously discusses unconventional and satirical methods for preventing hair loss, such as using coffee and mayonnaise on the scalp. It mentions caffeine as a DHT blocker and jokes about various coffee-related treatments.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

A user plans a drug-free hair transplant while waiting for future treatments like stem cell therapies, which are projected to be available between 2028 and 2030. Many users express skepticism about the availability of new treatments, suggesting that relying on them is risky and that finasteride remains the most effective option.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

Finasteride is not effectively stopping hair loss for the user, who is considering alternatives like Dutasteride, Minoxidil, and microneedling, but is hesitant about surgery or hair systems. The user expresses frustration with the lack of effective treatments for male pattern baldness.

The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with users sharing experiences of shedding and gradual transition methods. Some users report continued shedding, while others are hopeful for thicker hair after the switch.

Switching to dutasteride as a hair loss prevention treatment, along with minoxidil, dermarolling and nizoral shampoo, and the potential benefits and side effects of using finasteride and/or dutasteride in combination with topical anti-androgens like RU58841.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

A user with diffuse thinning alopecia uses a custom full cap wig for an active lifestyle, costing $450 and lasting about 10 months. They share their positive experience with the wig as an alternative for those for whom treatments like Minoxidil, finasteride, or RU58841 don't work.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation discusses alternative hair loss treatments beyond the commonly used Minoxidil and Finasteride. One user is trying diclofenac gel, caffeine + antioxidant serum, finasteride, ketoconazole shampoo, and has stopped using Minoxidil due to ineffectiveness, while another user has adopted lifestyle changes like exercise, diet, stress reduction, and topical caffeine, along with scalp massages and microneedling.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

A user successfully halted hair loss using finasteride for 17 years and recently switched to dutasteride for stronger DHT suppression. They experienced no major side effects, maintained a full head of hair, and fathered three children without issues.

The user has been using dutasteride, minoxidil, and RU58841 for a year to stabilize hair loss and is considering a hair transplant. They are taking 5mg of oral minoxidil daily and are unsure of its effectiveness but have noticed more hair than a year ago.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

The conversation discusses concerns about weight gain potentially linked to biotin, saw palmetto, and pumpkin seed supplements, with users generally doubting the supplements are the cause. One user stopped taking saw palmetto due to side effects but did not notice improved results.